JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jazz Pharmaceuticals plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$208.43−1.80 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Jazz Pharmaceuticals plc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $4.02B | $3.82B | $3.74B | $3.64B | $3.08B | $2.35B | $2.14B | $1.87B | – | – | 94.2% | +5.3% |
| Total Neuroscience | $2.88B | $2.70B | $2.71B | $2.76B | – | – | – | – | – | – | 67.5% | +6.7% |
| Xywav | $1.66B | $1.47B | $1.27B | $958.43M | $535.30M | $15.26M | $0 | $0 | – | – | 38.8% | +12.5% |
| Total Oncology | $1.13B | $1.11B | $1.02B | $873.84M | – | – | – | – | – | – | 26.5% | +1.6% |
| Epidiolex/Epidyolex | $1.06B | $972.42M | $845.47M | $736.40M | $463.65M | $0 | $0 | – | – | – | 24.8% | +8.9% |
| Rylaze/Enrylaze | $402.92M | $410.85M | $394.23M | $281.66M | – | – | – | – | – | – | 9.4% | -1.9% |
| Zepzelca | $307.31M | $320.32M | $289.53M | $269.91M | $246.81M | $90.38M | $0 | $0 | – | – | 7.2% | -4.1% |
| Royalties and contract revenues | $245.74M | $247.79M | $97.26M | $17.95M | $15.24M | $16.91M | $26.16M | $21.45M | $17.29M | $10.71M | 5.8% | -0.8% |
| High-sodium oxybate AG royalty revenue | $211.73M | $217.58M | $75.92M | $0 | $0 | – | – | – | – | – | 5.0% | -2.7% |
| Defitelio/defibrotide | $199.39M | $216.57M | $184.00M | $194.29M | $197.93M | $195.84M | $172.94M | $149.45M | $133.65M | $108.95M | 4.7% | -7.9% |
| Vyxeos | $146.71M | $162.60M | $147.50M | $127.98M | $134.06M | $121.11M | $121.41M | $100.84M | $33.79M | $0 | 3.4% | -9.8% |
| Xyrem | $146.03M | $233.82M | $569.73M | $1.02B | $1.27B | $1.74B | $1.64B | $1.40B | $1.19B | $1.11B | 3.4% | -37.5% |
| Modeyso | $48.04M | $0 | $0 | – | – | – | – | – | – | – | 1.1% | – |
| Other royalty and contract revenues | $34.01M | $30.21M | $21.34M | $17.95M | – | – | – | – | – | – | 0.8% | +12.6% |
| Ziihera | $24.81M | $1.05M | $0 | $0 | – | – | – | – | – | – | 0.6% | +2260.6% |
| Sativex | $16.28M | $18.88M | $19.67M | $16.83M | $12.71M | $0 | $0 | – | – | – | 0.4% | -13.8% |
| Other | $14.17M | $11.47M | $13.85M | $6.64M | $9.80M | $6.84M | $17.55M | $39.59M | $49.92M | $30.90M | 0.3% | +23.5% |
| Prialt | – | – | – | – | – | – | – | $20.84M | $27.36M | $29.12M | – | – |
| Erwinaze/Erwinase | – | – | $0 | $0 | $69.38M | $147.14M | $177.47M | $174.74M | $197.34M | $200.68M | – | – |
| Psychiatry | – | – | – | – | – | – | – | – | – | $17.65M | – | – |
| Defitelio/defibrotide | – | – | – | – | – | – | – | – | $133.65M | $108.95M | – | – |
| Product sales, net | – | – | – | – | – | – | $2.14B | $1.87B | $1.60B | $1.48B | – | – |
| Sunosi | – | $0 | $0 | $28.84M | $57.91M | $28.33M | $3.71M | $0 | $0 | – | – | – |
| Oncology | – | – | $1.02B | $873.84M | $733.81M | $554.46M | $471.81M | $425.02M | – | – | – | – |
| Total Neuroscience | – | – | $2.71B | $2.76B | $2.34B | $1.79B | $1.65B | $1.40B | – | – | – | – |
| Total Oxybate | – | – | – | $1.98B | $1.80B | $1.76B | $1.64B | $1.40B | – | – | – | – |
| Rylaze | – | – | $394.23M | $281.66M | $85.63M | $0 | $0 | – | – | – | – | – |
| Other royalty and contract revenues | – | – | $21.34M | $17.95M | $15.24M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.83B | $3.66B | $3.49B | $3.37B | $2.82B | $2.14B | $1.96B | $1.73B | $1.46B | $1.36B | 89.8% | +4.7% |
| Europe | $341.12M | $312.71M | $269.24M | $239.64M | $230.16M | $175.21M | $150.20M | $125.91M | $125.62M | $108.30M | 8.0% | +9.1% |
| All other | $94.87M | $96.14M | $74.98M | $49.36M | $43.84M | $43.82M | $47.40M | $37.44M | $29.61M | $23.75M | 2.2% | -1.3% |
From the segment and revenue-disaggregation notes of Jazz Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.